News

Mirikizumab superior to Cosentyx in a Phase III study for patients with moderate to severe plaque psoriasis.- Eli Lilly

Read time: 1 mins

Published:18th Jul 2020

Eli Lilly and Company announced that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 (non-inferiority) and Week 52 (superiority) in the OASIS-2 study. OASIS-2 is a multicenter randomized, double-blind, placebo-controlled study comparing the efficacy and safety of mirikizumab to placebo and Cosentyx in patients with moderate to severe plaque psoriasis. The safety profile was consistent with previously disclosed results for mirikizumab and known safety findings of other drugs in the IL23p19 class. The full OASIS-2 study results will be disclosed at future congresses..

Condition: Psoriasis

Type: drug

Learning Zone Homepage

Psoriasis Academy

When it comes to psoriasis, a knowledgeable healthcare professional is highly valued by patients (Pariser et al., 2016). With this in mind, we created The Psoriasis Academy, an online hub featuring succinct and easily accessible information for all healthcare professionals who want to know more about psoriasis and keep up to date with the latest developments.

Learning Zone Homepage

Improving treatment options for childhood psoriasis

This Learning Zone introduces you to our young patient Mia who, along with our paediatric psoriasis experts, helps us to describe the burden of childhood psoriasis for patients and their families, particularly the difficulties around diagnosis, comorbidities and limited treatment options.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Positive phase III topline results from Study 501 evaluating lumateperone as adjunctive therapy in patients with major depressive disorder

Intra-Cellular Therapies, Inc. a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced positive topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

2 mins

Drug news

FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced the FDA approved Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato

1 min

Drug news

Imfinzi (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 phase III trial

Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC)

1 min

See all news